↑ トップへ ← 戻る

 Drug(薬物リスト) ALL | DrugBank 

   e.g. "Sirolimus", "アダリムマブ"    Synonyms (Drugs) were also searched for.

A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z other

44 / 1,666 drugs found* Show info (disease name, etc.) on mouse-over.
 No.   DrugBank   薬物名(臨床試験情報から抽出)   KEGG DRUG  KEGG GENES  KEGG PATHWAY   指定難病告示番号
 1   AQX-1125  3件: Aqx-1125; Aqx-1125 100 mg; Aqx-1125 200 mg;   -   -   -   1件:
226
 2   Adalimumab  51件: Adalimumab; Adalimumab injection [humira]; Adalimumab (ada); Adalimumab (humira); Adalimumab (humira®); Adalimumab (up to 9 months exposure); Adalimumab 40 mg; Adalimumab 40 mg subcutaneous (sc) every other week (eow); Adalimumab 40mg q2w; Adalimumab 80 mg; Adalimumab pfs and pen; Adalimumab with methotrexate; Adalimumab-eu; Adalimumab-pfizer; Anti-tnf therapy (etanercept or adalimumab); Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar product to adalimumab; Double-blind adalimumab; Etanercept or adalimumab; Humira (adalimumab); Humira 40mg solution for injection in pre-filled syringe (adalimumab); Humira® (adalimumab); Infliximab, etanercept, adalimumab; Methotrexate,adalimumab; New formulation adalimumab; Open-label adalimumab; Open-labeladalimumabrescue; Sb5 (proposed biosimilar to adalimumab); Tnf blockers (infliximab, adalimumab, etanercept); Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Adalimumab (40 mg); Adalimumab (d2e7); Adalimumab 40 mg eow or ew; Adalimumab and infliximab; Adalimumab injection; Adalimumab prn; Anti-tnf:adalimumab (subcutaneus); Application of adalimumab; Azathioprine or adalimumab and infliximab; Db adalimumab 40 mg eow; Db adalimumab 40 mg ew; Fitc-adalimumab; Infliximab and adalimumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab, adalimumab, certolizumab pegol; Ol adalimumab 40 mg; Start adalimumab in monotherapy; Treatment with adalimumab; Adalimumab 40 mg sc every other week; Adalimumab, etanercept, golimumab or infliximab; Gp2017 (adalimumab biosimilar);   D02597   1件: TNF   9件: Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   15件:
19,
37,
41,
46,
56,
84,
96,
97,
151,
160,
164,
222,
226,
269,
271
 3   Amitriptyline  3件: Amitriptyline; Amitriptyline, fluoxetine and tramadol alone (control group); Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group);   D00809
 D07448 
 2件: SLC6A2, SLC6A4   2件: Serotonergic synapse, Synaptic vesicle cycle   3件:
78,
226,
299
 4   Botulinum toxin type A  3件: Botulinum toxin type a; Clostridium botulinum toxin type a; Botulinum toxin type a (nabota®) injection into the gastrocnemius muscle;   D00783   1件: SNAP25   1件: Synaptic vesicle cycle   13件:
2,
5,
6,
7,
13,
15,
17,
36,
51,
70,
113,
149,
226
 5   Buckwheat  1件: Buckwheat;   -   -   -   1件:
226
 6   Bupivacaine  9件: Bupivacaine; Bupivacaine hydrochloride; Levobupivacaine; Liposomal bupivacaine; Bupivacaine/epinephrine/dexamethasone; Lap tap bupivacaine/epinephrine; Us tap bupivacaine/epinephrine; Bupivacaine injection 0.5%; Bupivacaine & triamcinolone acetonide;   D01450
 D07552 
 1件: SCN1A   1件: Dopaminergic synapse   7件:
46,
53,
70,
96,
168,
226,
298
 7   Capsaicin  4件: Capsaicin; Capsaicin challenge; Capsaicin vapor; Qutenza (8% capsaicin);   D00250   1件: TRPV1   1件: Neuroactive ligand-receptor interaction   6件:
2,
6,
19,
86,
113,
226
 8   Certolizumab pegol  11件: Certolizumab pegol; 99mtc-s-hynic certolizumab pegol; Certolizumab pegol (cdp870, tradename cimzia); Certolizumab pegol (cdp870, tradename cimzia)(prefilled syringes at the dose of 200mg); Certolizumab pegol (czp); Certolizumab pegol + methotrexate (mtx); Certolizumab pegol (cdp870); Certolizumab pegol (rinn); Certolizumab pegol 400 mg; Infliximab, adalimumab, certolizumab pegol; Cimzia certolizumab pegol 200 mg/ml solution for injection;   D03441   1件: TNF   10件: Adipocytokine signaling pathway, Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway, Toll-like receptor signaling pathway   6件:
37,
46,
96,
97,
226,
271
 9   Chondroitin sulfate  4件: Chondroitin sulfate; 2% sodium chondroitin sulfate; Hyaluronic acid and chondroitin sulfate; Hyaluronic acid/chondroitin sulfate;   D00080   -   -   2件:
96,
226
 10   Ciclosporin  7件: Ciclosporin; Ciclosporina; Ciclosporine; Aerolised liposomal ciclosporin a; Ciclosporin (ciclosporinium); Ciclosporin a; Ciclosporine, ciclosporina;   D00184   5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   7件: Cellular senescence, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation   44件:
11,
14,
19,
20,
26,
28,
36,
38,
39,
40,
41,
42,
45,
46,
49,
50,
53,
55,
56,
58,
60,
61,
62,
63,
64,
65,
90,
95,
97,
113,
162,
164,
222,
223,
226,
228,
234,
269,
274,
283,
284,
285,
302,
326
 11   Dexmedetomidine  8件: Dexmedetomidine; Dexmedetomidine hydrochloride infusion; Dexmedetomidine group; Dexmedetomidine hydrochloride; Dexmedetomidine and fentanyl; Dexmedetomidine 1; Dexmedetomidine 2; Dexmedetomidine 3;   D00514
 D01205 
 3件: ADRA2A, ADRA2B, ADRA2C   1件: Neuroactive ligand-receptor interaction   11件:
2,
4,
6,
21,
34,
70,
113,
212,
215,
226,
280
 12   Dimethyl sulfoxide  1件: Dimethyl sulfoxide;   D01043   -   -   1件:
226
 13   Epinephrine  4件: Epinephrine; Bupivacaine/epinephrine/dexamethasone; Lap tap bupivacaine/epinephrine; Us tap bupivacaine/epinephrine;   D00095
 D00996
 D02149 
 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3   7件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   9件:
6,
13,
46,
86,
96,
168,
226,
231,
256
 14   Estradiol  9件: Estradiol; Estradiol hemihydrate; Ethinylestradiol; Ethinyl estradiol; Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); 5% lidocaine/5 mg/ml estradiol compound cream; Estradiol 2 mg; Loestrin (norethindrone acetate and ethinyl estradiol); Ortho-cyclen, ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg;   D00105
 D01413
 D01617
 D01953
 D04061
 D04063
 D04064
 D04065 
 2件: ESR1, ESR2   2件: Endocrine and other factor-regulated calcium reabsorption, Estrogen signaling pathway   5件:
13,
46,
49,
226,
299
 15   Fospropofol  4件: Fospropofol; Fospropofol (lusedra®) 10; Fospropofol (lusedra®) 12; Fospropofol (lusedra®) 6.5;   D04257   -   -   1件:
226
 16   Gabapentin  7件: Gabapentin; Gabapentina; Gabapentina kern pharma; Gabapentine; Gabapentine 300mg; Transdermal fentanyl matrix, gabapentin; Gabapentin prescriptions;   D00332   5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1   2件: GABAergic synapse, MAPK signaling pathway   7件:
6,
13,
19,
70,
97,
226,
298
 17   Gefapixant  2件: Gefapixant; Gefapixant first,;   D11349   1件: P2RX3   1件: Neuroactive ligand-receptor interaction   2件:
85,
226
 18   Glycine  4件: Glycine; Flolan tm and glycine diluent; Flolan™ and glycine diluent; Glycine buffer;   D00011   -   -   4件:
35,
86,
226,
299
 19   Heparin  7件: Heparin; Low molecular weight heparin calcium injection; Alkalinized lidocaine-heparin; Bladder instillation with heparin/ lidocaine; Heparin sodium; Heparin 25mg inhalation powder, hard capsule; Intralipid/heparin;   D07510   1件: SERPINC1   1件: Complement and coagulation cascades   11件:
60,
70,
79,
84,
107,
224,
226,
280,
299,
316,
317
 20   Hyaluronic acid  5件: Hyaluronic acid; Standard care hyaluronic acid eye drops; Hyaluronic acid and chondroitin sulfate; Hyaluronic acid/chondroitin sulfate; Hyaluronic acid inhalation solution;   D08043   -   -   7件:
46,
53,
70,
97,
226,
231,
299
 21   Hydrogen  4件: Hydrogen; 3- (9,10- didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate; Lisuride hydrogenmaleate; Tch346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt);   -   -   -   5件:
5,
6,
17,
97,
226
 22   Ketorolac  2件: Ketorolac; Ketorolac tromethamine;   D00813
 D08104 
 2件: PTGS1, PTGS2   1件: Arachidonic acid metabolism   2件:
70,
226
 23   Lidocaine  8件: Lidocaine; Local anesthesia (lidocaine hydrochloride); Lidocaine patch 5%; Lidocaine injection 2%; 5% lidocaine/5 mg/ml estradiol compound cream; Alkalinized lidocaine-heparin; Bladder instillation with heparin/ lidocaine; Lidocaine releasing intravesical system - liris®;   D00358
 D02086
 D08127 
 2件: SCN1A, SCN5A   2件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse   10件:
6,
13,
46,
84,
86,
97,
168,
226,
231,
256
 24   Metoprolol  8件: Metoprolol; Metoprolol tartrate 50 mg; Metoprolol succinate; Metoprolol succinate + doxazosin; Metoprololsuccinat orion 25mg; Metoprololsuccinat ”orion” 25mg; Tesofensine/metoprolol; Metoprolol tartrate oral tablet;   D00601
 D02358
 D05011 
 1件: ADRB1   2件: Adrenergic signaling in cardiomyocytes, Neuroactive ligand-receptor interaction   7件:
17,
57,
58,
66,
113,
193,
226
 25   Mirabegron  1件: Mirabegron;   D09535   1件: ADRB3   2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction   3件:
6,
13,
226
 26   Mycophenolate mofetil  17件: Mycophenolate mofetil; Mycophenolate mofetil (cellcept); Mycophenolate mofetil [cellcept]; Mycophenolate mofetil (mmf) 3 g/day; Mycophenolate mofetil 2 g/day; Cellcept (mycophenolate mofetil); Mycophenolate mofetil,methotrexate; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Mycophenolate mofetil (mmf); Mycophenolate mofetil plus lower dose of prednisone; Azathioprine or mycophenolate mofetil; Mycophenolate mofetil orally 1000 mg twice a day (bid); Mycophenolate mofetil, low dose steroid; Prednisolone and mycophenolate mofetil; Mycophenolate mofetil(mmf); Cyclosporine combine with mycophenolate mofetil; Prednisone and mycophenolate mofetil;   D00752
 D05094
 D05095 
 2件: IMPDH1, IMPDH2   1件: Purine metabolism   32件:
2,
11,
13,
14,
19,
20,
28,
35,
36,
42,
43,
45,
49,
51,
53,
60,
62,
65,
66,
85,
95,
96,
162,
164,
222,
224,
226,
234,
283,
284,
285,
300
 27   Mycophenolic acid  2件: Mycophenolic acid; Mycophenolic acid mofetil;   D05096   2件: IMPDH1, IMPDH2   1件: Purine metabolism   34件:
2,
11,
13,
14,
19,
20,
28,
35,
36,
42,
43,
45,
49,
51,
53,
60,
62,
65,
66,
84,
85,
95,
96,
162,
164,
222,
224,
226,
228,
234,
283,
284,
285,
300
 28   Naloxone  8件: Naloxone; Oxycodone/naloxone prolonged release tablets; Naloxone hydrochloride; Oxycodone naloxone prolonged release tablets; Oxycodone/naloxone prolonged release t; Oxycodone/naloxone prolonged release tablets 10/5 mg; Oxycodone/naloxone prolonged release tablets 20/10 mg; Oxycodone/naloxone prolonged release tablets 5/2.5 mg;   D01340
 D08249 
 3件: OPRD1, OPRK1, OPRM1   2件: Morphine addiction, Neuroactive ligand-receptor interaction   2件:
6,
226
 29   Nortriptyline  1件: Nortriptyline;   D00816
 D08288 
 2件: SLC6A2, SLC6A4   2件: Serotonergic synapse, Synaptic vesicle cycle   2件:
6,
226
 30   Omalizumab  3件: Omalizumab; Omalizumab (xolair); Rituximab combined with omalizumab;   D05251   1件: FCER1A   2件: Asthma, Fc epsilon RI signaling pathway   6件:
53,
65,
98,
162,
226,
299
 31   Oxycodone  14件: Oxycodone; Oxycodone/naloxone prolonged release tablets; Pr oxycodone; Extended-release oxycodone; Oxycodone by patient-controlled analgesia (pca); Oxycodone hydrochloride; Oxycodone orion; Oxycodone naloxone prolonged release tablets; Oxycodone/naloxone prolonged release t; Oxycodone/naloxone prolonged release tablets 10/5 mg; Oxycodone/naloxone prolonged release tablets 20/10 mg; Oxycodone/naloxone prolonged release tablets 5/2.5 mg; Oxycodone/acetaminophen; Oxycodone depot ”sandoz”, depot tablets;   D03783
 D05312
 D05462 
 3件: OPRD1, OPRK1, OPRM1   1件: Neuroactive ligand-receptor interaction   7件:
6,
13,
46,
70,
226,
231,
298
 32   Oxygen  10件: Oxygen; Oxygen 40 %; Nitric oxide plus oxygen; Oxygen supplementation; Continuous oxygen; Medical air vs oxygen; Maternal hyperoxygenation; Medical grade oxygen; Perfluorinated gas/oxygen mixture; Helium / oxygen mixed gas inhalation therapy;   D00003   -   -   18件:
5,
6,
17,
46,
49,
70,
84,
85,
86,
88,
90,
96,
97,
193,
211,
226,
299,
330
 33   Oxytocin  6件: Intranasal oxytocin; Oxytocin; Intranasal oxytocin (in-oxt); Oxytocin (oxt) continuous; Oxytocin 24iu; Oxytocin 48iu;   D00089   1件: OXTR   2件: Neuroactive ligand-receptor interaction, Oxytocin signaling pathway   4件:
127,
193,
206,
226
 34   PD-0299685  0件:   -   -   -   1件:
226
 35   Pentosan Polysulfate  3件: Pentosan polysulfate; Pentosan polysulfate sodium; Pentosan polysulfate sodium 100 mg;   D05428   -   -   3件:
19,
26,
226
 36   Propiverine  2件: Propiverine; Propiverine hydrochloride;   D08441   9件: CACNA1C, CACNA1D, CACNA1F, CACNA1S, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5   3件: Calcium signaling pathway, Cholinergic synapse, Neuroactive ligand-receptor interaction   1件:
226
 37   Sildenafil  25件: Sildenafil; 5% sildenafil cream; Sildenafil 20mg; Sildenafil 20mg and bosentan 62.5mg; Sildenafil citrate; Sildenafil therapy; Sildenafil (50 mg); Sildenafil and losartan; 20 mg sildenafil citrate by mouth; Access program - sildenafil citrate, viagra, revatio; Bosentan and sildenafil; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Oral sildenafil; Sildenafil (as citrate); Sildenafil (revatio); Sildenafil (revatio) 20 mg tid; Sildenafil citrate (uk-92,480); Sildenafil singly or in association with bosentan; Sitaxsentan and sildenafil; Sodium tanshinone iia sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth; Tadalafil and sildenafil; Sildenafil 20 mg tablets; Acute (1 hour) sildenafil; Sildenafil 40mg oral capsule; Sub-chronic (4 weeks) sildenafil;   D02229
 D08514 
 1件: PDE5A   1件: cGMP-PKG signaling pathway   16件:
6,
46,
50,
51,
85,
86,
96,
113,
210,
211,
212,
225,
226,
278,
294,
299
 38   Sulfate ion  0件:   -   -   -   22件:
2,
6,
11,
13,
26,
34,
36,
46,
49,
60,
61,
64,
66,
79,
86,
96,
222,
226,
265,
296,
297,
299
 39   Tacrolimus  13件: Tacrolimus; Tacrolimus capsule; Interferon beta-1b and tacrolimus; Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Tacrolimus (prograf®); Tacrolimus with methotrexate; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Lcp-tacro (tacrolimus); Rectal tacrolimus; Tacrolimus capsules; Tacrolimus combined with prednisone; Tacrolimus and mmf; Tacrolimus prolonged-release hard capsules;   D00107
 D08556 
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   7件: Cellular senescence, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation   30件:
2,
11,
13,
36,
46,
49,
50,
51,
53,
60,
61,
62,
65,
66,
85,
86,
95,
96,
97,
113,
151,
158,
164,
222,
224,
226,
228,
283,
284,
299
 40   Tanezumab  1件: Tanezumab;   D09387   -   -   2件:
226,
298
 41   Tramadol  5件: Tramadol; Tramadol hydrochloride + acetaminophen; Amitriptyline, fluoxetine and tramadol alone (control group); Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group); Tramadol /acetaminophen;   D01355
 D08623 
 1件: OPRM1   1件: Neuroactive ligand-receptor interaction   5件:
46,
70,
78,
226,
271
 42   Triamcinolone  10件: Triamcinolone; Triamcinolone acetonide; Triamcinolone hexacetonid (lederspan); Triamcinolone hexacetonide; Triamcinolone hexacetonide (lederspan); Triamcinolone acetonide and normal saline solution; Bladder instillation with triamcinolone acetonide; Bladder instillation without triamcinolone acetonide; Bupivacaine & triamcinolone acetonide; Intra plexus triamcinolone and bupivicaine injection;   D00385
 D00983
 D00984
 D00985
 D06216 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   18件:
6,
10,
13,
35,
40,
41,
42,
43,
44,
45,
46,
56,
70,
90,
96,
97,
226,
298
 43   Tromethamine  2件: Ketorolac tromethamine; Tromethamine;   D00396   -   -   3件:
51,
226,
299
 44   Water  13件: 5% glucose water solution; Water; Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; 15 o water; Water for injection; 15-o labeled water; Pl 12185/0002 & pl 12185/0005(water for injection); Dextrose, 5% in water; High water intake; Lactose in water; Water for injections; Water for injections, ep;   D00001   -   -   22件:
2,
5,
6,
13,
17,
19,
28,
35,
46,
53,
57,
63,
65,
67,
78,
84,
97,
193,
226,
271,
278,
299

先頭へ